Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016. Sobi has since been building its immunology pipeline (rare disease drug Gamifant, U.S. rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and hematology pipeline outside of hemophilia (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).

Financial Strength

5/10

Name	Current	Vs Industry
Cash-To-Debt	0.03
Equity-to-Asset	0.48
Debt-to-Equity	0.54
Debt-to-EBITDA	2.63
Interest Coverage	3.09
Piotroski F-Score	5/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	2.24	Distress Grey Safe
Beneish M-Score	-2.49	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

9/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	11.5
	3-Year EBITDA Growth Rate	1.1
	3-Year EPS without NRI Growth Rate	-2.5
	3-Year Book Growth Rate	15.1
	Future 3-5Y EPS without NRI Growth Rate	26.85
	Future 3-5Y Total Revenue Growth Rate	9.5

Momentum Rank

	Name	Current	Vs Industry		Vs History
	5-Day RSI	67.47
	9-Day RSI	55.85
	14-Day RSI	53.67
	6-1 Month Momentum %	32.35

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	0.71
	Quick Ratio	0.5
	Cash Ratio	0.03
	Days Inventory	254.68
	Days Sales Outstanding	74.49
	Days Payable	57.44

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	3.77
	Dividend Payout Ratio	1.33
	Forward Dividend Yield %	3.77
	5-Year Yield-on-Cost %	3.77
	3-Year Average Share Buyback Ratio	-3.2
	Shareholder Yield %	-19.6

Profitability Rank

8/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	76.34
	Operating Margin %	17.29
	Net Margin %	9.26
	FCF Margin %	10.09
	ROE %	6.68
	ROA %	3.03
	ROIC %	4.37
	ROC (Joel Greenblatt) %	904.75
	ROCE %	7.17
	Years of Profitability over Past 10-Year	9

GF Value Rank

3/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	44.34
	Forward PE Ratio	28.82
	PE Ratio without NRI	36.24
	Shiller PE Ratio	37.47
	Price-to-Owner-Earnings	41.2
	PEG Ratio	4.77
	PS Ratio	4.07
	PB Ratio	2.66
	Price-to-Free-Cash-Flow	42.14
	Price-to-Operating-Cash-Flow	20.07
	EV-to-EBIT	29.39
	EV-to-Forward-EBIT	23.24
	EV-to-EBITDA	15.65
	EV-to-Forward-EBITDA	13.2
	EV-to-Revenue	4.94
	EV-to-Forward-Revenue	4.81
	EV-to-FCF	49.39
	Price-to-Projected-FCF	2.28
	Price-to-DCF (Earnings Based)	2.67
	Price-to-DCF (FCF Based)	3.11
	Price-to-Median-PS-Value	0.8
	Earnings Yield (Greenblatt) %	3.4
	FCF Yield %	2.42
	Forward Rate of Return (Yacktman) %	5.56

Financials (Next Earnings Date:2024-07-16)

Annual Quarterly TTM

SWOBY's 30-Y Financials

AAPL

Income Statement Breakdown

Annual Quarterly

No Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

No Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

No Enough Data

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

No Enough Data

Guru Trades

See Details

Insider Trades

See Details

Gurus Latest Trades with OTCPK:SWOBY

No Available Data

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015

Swedish Orphan Biovitrum AB Executives

Details

GF Value: $12.18

SWOBY

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 3 Severe warning signs with SWOBY. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil $)	2,186.63
	EPS (TTM) ($)	0.305
	Beta	0
	Volatility %	0
	14-Day RSI	53.67
	14-Day ATR ($)	0.233148
	20-Day SMA ($)	13.35825
	12-1 Month Momentum %	0
	52-Week Range ($)	10 - 16.5
	Shares Outstanding (Mil)	679.74

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	5
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Swedish Orphan Biovitrum AB Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Swedish Orphan Biovitrum AB Stock Events

Financials Calendars

	Event	Date	Price($)
No Event Data

Swedish Orphan Biovitrum AB Frequently Asked Questions

What is Swedish Orphan Biovitrum AB(SWOBY)'s stock price today?

The current price of SWOBY is $13.25. The 52 week high of SWOBY is $16.50 and 52 week low is $10.00.

When is next earnings date of Swedish Orphan Biovitrum AB(SWOBY)?

The next earnings date of Swedish Orphan Biovitrum AB(SWOBY) is 2024-07-16.

Does Swedish Orphan Biovitrum AB(SWOBY) pay dividends? If so, how much?

The Dividend Yield % of Swedish Orphan Biovitrum AB(SWOBY) is 3.77% (As of Today), Highest Dividend Payout Ratio of Swedish Orphan Biovitrum AB(SWOBY) was 1.33. The lowest was 0. And the median was 0. The Forward Dividend Yield % of Swedish Orphan Biovitrum AB(SWOBY) is 3.77%. For more information regarding to dividend, please check our Dividend Page.

Press Release

	Subject	Date
No Press Release

Headlines

No news.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.